Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 4/20 | 0.53 |
| ▸ | MAG | P20916 | 5/20 | 0.48 |
| ▸ | SELL | P14151 | 1/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.47 |
| ▸ | CD22 | P20273 | 10/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17988586 | 0.94 | SELL (0.53) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL17988604 | 0.92 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL18733276 | 0.90 | CD22 (0.43) | SIGLEC7MAGCD22 | |
| SCHEMBL18732828 | 0.90 | CD22 (0.43) | SIGLEC7MAGCD22 | |
| SCHEMBL31668635 | 0.90 | CD22 (0.43) | SIGLEC7MAGCD22 | |
| SCHEMBL16348264 | 0.90 | SIGLEC7 (0.50) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL17199608 | 0.90 | SIGLEC7 (0.50) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL15958878 | 0.90 | SIGLEC7 (0.50) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL15962626 | 0.90 | SIGLEC7 (0.50) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL15473997 | 0.90 | SIGLEC7 (0.59) | SIGLEC7MAGSELLSELPCD22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9237764-B2 | Production of 6′-O-sialyllactose and intermediates | GLYCOM A/S (DK) | 2016-01-19 | — | — | US | disclosed |
| US-20140057868-A1 | CATALYTIC HYDROGENOLYSIS OF A COMPOSITION OF A MIXTURE OF OLIGOSACCHARIDE PRECURSORS AND USES THEREOF | GLYCOM A/S (DK) | 2014-02-27 | — | — | US | disclosed |
| US-20140046044-A1 | NOVEL GLYCOSYL PHOSPHITES | GLYCOM A/S (DK) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057868-A1 | CATALYTIC HYDROGENOLYSIS OF A COMPOSITION OF A MIXTURE OF OLIGOSACCHARIDE PRECURSORS AND USES THEREOF | MGAM, SI, GALK1 | SIGLEC7 867/4885MAG 1980/4885SELL 3438/4885 |
| US-20140046044-A1 | NOVEL GLYCOSYL PHOSPHITES | GPI, FUT5, UGGT1 | SIGLEC7 78/4885MAG 344/4885SELL 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.